Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comorbidities and safety in a cohort of patients with progressive non-active form of multiple sclerosis treated with MD1003

Trial Profile

Comorbidities and safety in a cohort of patients with progressive non-active form of multiple sclerosis treated with MD1003

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Oct 2018 New trial record
    • 12 Oct 2018 Results assessing the effectiveness of a 12-month treatment with MD1003 on dexterity, cognition, and quality of life (QOL) measures presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Results identifying side effects and comorbidities in a cohort of patients with progressive non-active form of MS presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top